Korean J Hematol.  2011 Mar;46(1):57-58. 10.5045/kjh.2011.46.1.57.

A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma

• Kim SJ

• KMID: 2252022
• DOI: http://doi.org/10.5045/kjh.2011.46.1.57

Abstract

No abstract available.

MeSH Terms

Antibodies, Monoclonal, Murine-Derived
B-Lymphocytes
Lymphoma, B-Cell
Rituximab
Antibodies, Monoclonal, Murine-Derived

Reference

1. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998; 339:21–26. PMID: 9647875.

2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:235–242. PMID: 11807147.

3. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007; 25:787–792. PMID: 17228021.

4. Hong J, Kim AJ, Park JS, et al. Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean J Hematol. 2010; 45:253–259. PMID: 21253427.

5. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008; 26:2258–2263. PMID: 18413640.